Loading
The fifth-edition brain tumour classification makes molecular markers such as IDH mutation, 1p/19q codeletion and methylation class central to diagnosis, renaming and regrading many tumours, including separating IDH-mutant astrocytoma from glioblastoma.
Summary of the 2021 WHO classification of central nervous system tumours introducing integrated histological and molecular diagnoses, Arabic numeral grading within tumour types, new tumour types and families (paediatric-type diffuse gliomas, molecularly defined ependymomas and medulloblastoma groups), and grading of IDH-mutant astrocytoma up to grade 4 with CDKN2A/B deletion.
Every brain tumour page on this site uses these names and grades; a tumour called glioblastoma before 2021 may now be an IDH-mutant astrocytoma with a different outlook and treatment.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares Neuro-Oncology, Central nervous system germ cell tumours (germinoma and non-germinomatous).
Shares Neuro-Oncology, Central nervous system germ cell tumours (germinoma and non-germinomatous).
Shares Neuro-Oncology, Meningioma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH).
Shares Central nervous system germ cell tumours (germinoma and non-germinomatous), Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Astrocytoma, IDH-mutant (grades 2 to 4), Paediatric high-grade glioma (excluding diffuse midline glioma).
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.